NeuroVive Pharmaceutical AB Interim report January – September 2018
KL1333 approved for phase I clinical trial
Press releases
NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio
NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issue
NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects
NeuroVive Pharmaceutical AB Interim report January – September 2017
Continued positive trend for NeuroSTAT® Business operations
NeuroVive Pharmaceutical AB Interim report January – June 2017
Strategic in-licensing broadens the project portfolio
NeuroVive Pharmaceutical AB Interim report January – March 2017
Broadened project portfolio
NeuroVive Pharmaceutical AB Year End Report January – December 2016
Important steps forward and new research collaborations
NeuroVive Pharmaceutical AB Interim Report January – September 2016
New business model generates opportunities
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]
NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015
Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...